FEATURED COMPANIES
- CanSino Biologics, Inc.
- Gamaleya Institute
- Inovio Pharmaceuticals
- Johnson & Johnson
- Moderna, Inc.
- Novavax, Inc.
Global COVID-19 Vaccines Market to Reach 9.7 Billion Doses by 2025
Global COVID-19 annual vaccine doses estimated at 11 million doses in 2020 will reach 9.7 billion doses by 2027, displaying at a CAGR of 4.8% over the analysis period 2020-2025. In terms of value, the global market is projected to reach US$132.3 billion by the year 2025 up from the US$267 million estimated in the year 2020. Vaccine doses for children under 18 years, also analyzed as part of the report, will record a projected 90.5% CAGR over the analysis period.
Annual Doses in the U.S. to Plateau at 491 Million by 2025, While Africa Will Peak at 1.1 Billion Doses
Annual vaccine doses administered in the U.S. will plateau at 491 million doses by 2025 after peaking at 543 million doses in the year 2023. The country will record 2.1% CAGR for the period 2020 through 2025. China and Rest of Latin America will recorded the highest growth of 8.1% and 8.7% respectively over the said analysis period. Africa will remain the last region to catch up with the vaccine race. With just 823 million annual doses in 2021, the region is projected to record over 1.1 billion annual doses by the year 2025. In terms of value, annual vaccine doses in the U.S. is estimated at US$16 billion in year 2021, while Africa at the other end of scale weighs in at just US$5 billion for the same year. India, the new epicenter of the global pandemic will record the highest annual vaccine doses of 2.2 billion only in the year 2023.
Vaccines Doses for Under 18 Years to Record 90.5% CAGR
Global annual vaccines doses for children under 18 years estimated at 296.6 million doses in the year 2021, will reach a projected 3.5 billion doses by the year 2025, trailing a 90.5% CAGR. Regions with a large base of young population will witness the fastest growth. Middle East, Africa and Asia are all forecast to grow at 120.5%, 145.1% and 96.7% CAGR respectively. In China and India annual doses administered in this demographic cluster will increase from 109 million doses in 2021 to peak at 1.3 billion doses by the year 2025.
Select Competitors (Total 335 Featured) -
- Moderna, Inc.
- Pfizer Inc./BioNTech
- AstraZeneca/University of Oxford
- Johnson & Johnson
- CanSino Biologics, Inc.
- China National Pharmaceutical Group Co., Ltd. (Sinopharm)
- Sinovac Biotech Ltd.
- Novavax, Inc.
- Inovio Pharmaceuticals
- Sanofi/GlaxoSmithKline
- Gamaleya Institute
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- CanSino Biologics, Inc.
- Gamaleya Institute
- Inovio Pharmaceuticals
- Johnson & Johnson
- Moderna, Inc.
- Novavax, Inc.
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. COVID-19 VACCINE DEVELOPMENT - A GLOBAL MARKET OVERVIEW
17. SELECT CORPORATE DEVELOPMENTS IN THE COVID-19 MARKET SPACE: 2021
III. COMPETITION
II. EXECUTIVE SUMMARY
1. COVID-19 VACCINE DEVELOPMENT - A GLOBAL MARKET OVERVIEW
- The Race Between the Virus & Vaccines Intensifies. Amidst this Chaotic Battle, Where Is The World Economy Headed in 2021?
- EXHIBIT 1: How Fast the World is Vaccinated Will Determine How Soon the Pandemic Will End: Global Number of Annual COVID-19 Vaccine Doses (In Million) for Years 2020 through 2025 by Geographic Region/Country - USA, Canada, Japan, China, Europe, Asia-Pacific (India and Rest of Asia-Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), Middle East, and Africa Markets
- EXHIBIT 2: World 5-Year Perspective for COVID-19 Vaccines by Geographic Region - Percentage Breakdown of Million Doses for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2020 & 2025
- EXHIBIT 3: World Current & Future Analysis for COVID-19 Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific (India and Rest of Asia-Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), Middle East, and Africa Markets - Independent Analysis of Annual Doses in US$ Million for Years 2020 through 2025
- EXHIBIT 4: World 5-Year Perspective for COVID-19 Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2020 & 2025
- Increased Hospital Admissions and Deaths Characterize Second and Third Wave
- EXHIBIT 5: Daily New Confirmed Cases (Per Million) by Select Country
- EXHIBIT 6: COVID-19 Cases Worldwide by Country: As on May 17, 2021
- EXHIBIT 7: COVID-19 Cases in the US by State: As on May 17, 2021
- With IMF's Upward Revision of Global GDP Forecasts for 2021, Most Companies Are Bullish about a Global Economic Comeback.
- EXHIBIT 8: World Economic Growth Projections (Real GDP, Annual % Change) for 2020 through 2022
- Unprecedented Crisis Prompts Biden Administration to Support Efforts to Waive Intellectual Property Rights for COVID-19 Vaccines
- EU Joins US in Quest to Waive COVID-19 Vaccine Patent Protections
- ASIA-PACIFIC
- Fresh Wave of COVID-19 Spiralling Out of Control in Asia-Pacific
- India Battles the Lethal Second Wave
- UNITED STATES
- Regional Spike in New Cases in US: Is a Fourth Wave of COVID-19 in Near Future
- EUROPE
- European Nations Ramp up Restrictions as Third Wave of COVID-19 Envelops Continent
- Germany Prolongs Lockdown until June, 2021
- France: Night Curfew & Regionalized ‘Lockdown Lite'
- COVID-19 Virus Can Adapt & Undergo ‘Escape Mutation' to Pose Vaccine Challenge
- Indian Variant of COVID-19 Virus Puts Healthcare System on Brink of Major Collapse
- Investigating the Virulence Profile of India's N440K Variant
- Is South African Variant a Formidable Threat?
- E484K Mutation Challenges Vaccine Developers
- Rising Cases in South Africa & Other Countries
- California Strain Emerges to be more Contagious and Deadly
- Is COVID-19 Virus Increasingly Resorting to Mutation to Outsmart Vaccines?
- Mutated COVID-19 Variant Makes Oxford-AstraZeneca Vaccine Rollout to Go Haywire in South Africa
- Pfizer COVID-19 Vaccine Demonstrates Low to Modest Level of Efficacy against South African Variant
- Pfizer/BioNTech Trailing a Third Covid-19 Shot to Provide Variant Protection
- Moderna's Variant-Specific Vaccine Candidate Ready for Clinical Study
- AstraZeneca Plans to Adapt Covid-19 Vaccine against New Emerging Variants
- Sinovac Vaccines Against Mutated Variants of Coronavirus to be Produced in 10 Weeks
- EXHIBIT 9: Roll-out Timeline of Select Frontrunners
- COVID-19 Vaccine Approval Details
- EXHIBIT 10: Production Capacity by Company for Frontrunners in Millions of Doses for 2021
- COVID-19 Vaccine Funding Details
- Pfizer/BioNTech's COVID-19 Vaccine Receives World's First Authorization
- UK Clinches the First Position in the World to Approve Pfizer's Vaccine
- After UK, Pfizer's Vaccine Gains Approval from the US and EU
- BioNTech to Scale up Vaccine Production to Fill Supply Gaps and Support Vaccination Efforts in the EU
- Novartis Inks Agreement with Pfizer-BioNTech to Support Covid-19 Vaccine Production
- After Pfizer, Moderna Vaccine Bags Coveted EUA from US FDA
- Moderna Kick-Starts Inoculation in the US
- AstraZeneca's Vaccine - Third Globally to Obtain Approval
- J&J's Single Shot Vaccination Resumes After Temporary Suspension
- Pfizer/BioNTech vs. Moderna vs. AstraZeneca vs. J&J Vaccine
- A Comparison of Pfizer, Moderna, and AstraZeneca COVID-19 Vaccine
- Johnson & Johnson's Adenovirus-based COVID-19 Vaccine vis-a-vis Moderna or Pfizer
- Limitations
- Russia Commences Mass Vaccination from Mid-December, 2020
- Russia's Sputnik V Receives Approval for People Aged over 60
- Chinese Vaccine Development Scenario
- China Awards Conditional Approval to First COVID-19 Vaccine from Sinopharm
- WHO Approves China`s Sinopharm Covid-19 vaccine for Emergency Use
- Global Production of COVID-19 Vaccine Accelerates as China's Vaccines Licensed to Overseas Partners
- Brazilian Authorities Approve Sinovac's CoronaVac
- AstraZeneca's Covishield and Bharat Biotech's Covaxin Receive Emergency Use Approval in India
- Sanofi Starts Trials of Second Vaccine after Disappointing Results of the First Vaccine
- EXHIBIT 11: COVID-19 VACCINES UNDER DEVELOPMENT
- EXHIBIT 12: COVID-19 Vaccine Candidates in Human Clinical Trials
- EXHIBIT 13: Vaccines in Pipeline by Technology
- EXHIBIT 14: Vaccine Technologies in Pre-Clinical Studies
- A Look into Other Key Vaccine Frontrunners
- CanSino Biologics, Inc. (China)
- CanSinoBIO Claims No Blood Clot Issues from COVID-19 Vaccine
- CanSino Initiates Phase 3 Trial of COVID-19 Vaccine Candidate in Mexico
- Novavax, Inc. (US)
- Novavax Experiences Further Approval Delays To Produce Covid-19 Vaccine
- Novavax Begins Crossover Arms for COVID-19 Vaccine Trials in UK and South Africa
- Sanofi/GlaxoSmithKline (France/UK)
- Merck & Co.
- Merck Discontinues Covid-19 Vaccines Development
- Global Vaccine Shortage Threatens to Slow Immunization Pace
- Covid-19 Vaccine Reported Side Effects
- Women
- Youngsters
- People with History of Covid-19 Infection
- New Virus Strains
- Vaccine Roll Out
- Vaccine Efficacy and Resistance
- Supply Challenges
- Logistics Challenges
- Distribution Challenges
- Anti-Vaccine Movement Poses Significant Threat
- COVID-19 Vaccine Approvals Shift All Eyes toward Pre-Order and Distribution Statistics
- EXHIBIT 15: Select Major COVID-19 Vaccine Doses (In Millions) Contracts by Various Countries for 2020-2021
- Mixing Covid-19 Vaccines to Increase Reactogenicity
- Delivering Vaccines to Developing and Under-developed Countries
- Emergence of Novel Disease Variants Likely to Spell Need for Booster Shots
- Long-Haul COVID-19 Holds Potential to Become a Public Health Issue
- Vaccine Passports - The New Concept for Travel and Premises Access Permission
- Vaccination Passport Idea
- Kids: A Key to COVID-19 Mitigation Efforts
- FDA Approves Pfizer-BioNTech Vaccine in Kids aged 12 to 15 Years Age (May, 2021)
- Moderna Begins Testing its Vaccine on Children Aged Below 12 Years (March, 2021)
- PMIS Risk among Infected Children Urges Critical Need for COVID-19 Vaccine
- Oxford University Halts AstraZeneca COVID-19 Vaccine Trial on Children over Perceived Safety Concerns
- EXHIBIT 16: World COVID-19 Vaccines for Under-18 Age Group by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific (India and Rest of Asia-Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), Middle East, and Africa Markets - Independent Analysis of Annual Doses in Millions for Years 2020 through 2025
- EXHIBIT 17: World COVID-19 Vaccines for Under-18 Age Group by Geographic Region - Percentage Breakdown of Million Doses for USA, Canada, Japan, China, Europe, Asia-Pacific (India and Rest of Asia-Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), Middle East, and Africa Markets for Years 2021 & 2025
- mRNA Vaccine Marks Dawn of New Era of Vaccines & Medical Therapies
- COVID-19 Vaccines Thrust RNA Technology for Future Outbreaks
- RNA Technology: Benefits & Potential for Future Outbreaks
- Key Challenges
- mRNA Vaccines Could Vanquish COVID-19 and Cancer
- Efforts to Target New Application Areas
- As Serious Candidate, mRNA Technology Warrants Attention from Scientific Community
- THE UNITED STATES
- Market Analysis
- US FDA Gives Nod to Pfizer and Moderna's Vaccine
- Moderna to Supply 100 Million more Doses of COVID-19 Vaccine to the US Government
- Lonza Announces Plans to Double Moderna COVID-19 Vaccine Output in Switzerland
- US Regulators Give Nod to Pfizer-BioNTech COVID-19 Vaccine for Ages 12 to 15
- Federal Health Agencies End Temporary Pause of J&J's Covid-19 Vaccine Use
- Positive Safety Review Prompts Walmart to Restart Johnson & Johnson COVID-19 Vaccinations
- Sanofi Joins Hands with Moderna to Produce COVID-19 Vaccines for Global Supply
- The ‘Operation Warp Speed' Program Expedites Vaccine Development
- EXHIBIT 18: US Government Deals with Vaccine Developers
- Market Analytics
- EXHIBIT 19: USA Current & Future Analysis for COVID-19 Vaccines Market: Annual Sales in Million Doses for the Years 2020 through 2025
- EXHIBIT 20: USA Current & Future Analysis for COVID-19 Vaccines Market: Annual Sales in US$ Million for the Years 2020 through 2025
- CANADA
- Market Analysis
- Vaccination Gathers Steam Across Canada
- EXHIBIT 21: Percentage (%) of Population Vaccinated (at least one dose) in Canada by Province/Territory As of May 3, 2021
- EXHIBIT 22: Vaccine Distribution in Canada by Vaccine Manufacturer (in '000s) As of April 29, 2021
- COVID-19 Vaccine Deals in Canada
- Pfizer Plans to Ramp up COVID-19 Vaccine Supply to Canada from May, 2021
- Canada Grants Approval to Pfizer's COVID-19 Shot for Use in Children in 12-15 Years Age Group
- Market Analytics
- EXHIBIT 23: Canada Current & Future Analysis for COVID-19 Vaccines Market: Annual Sales in Million Doses for the Years 2020 through 2025
- EXHIBIT 24: Canada Current & Future Analysis for COVID-19 Vaccines Market: Annual Sales in US$ Million for the Years 2020 through 2025
- JAPAN
- Market Analysis
- COVID-19 Vaccination Programs in Japan Move Forward at Snail's Pace
- Reasons Responsible for Setback
- Vaccine Timeline & Availability
- Japan Demands for Vaccine-Related Data
- People's Low Trust in Vaccines
- Japan's Efforts to Develop Indigenous Vaccines
- Japan to Step Up COVID-19 Immunization Drive to Cover Geriatric Population
- Japan Inks Deal with Pfizer to Secure 50 Million Additional Doses of COVID-19 Vaccine
- Japan Pushes Shipments of Pfizer's COVID-19 Shots to Vaccinate Elderly
- Coronavirus Vaccination Drive Timeline in Japan
- Takeda to Obtain Approval for Moderna's Vaccine
- AnGes Fast Tracks COVID-19 Vaccine Development Program for 2021 Rollout
- Japan Commences Production of AstraZeneca's Vaccine
- VLP Therapeutics Plans to Commence Clinical Trials for Low-Dose COVID-19 Vaccine in Japan
- Market Analytics
- EXHIBIT 25: Japanese Current & Future Analysis for COVID-19 Vaccines Market: Annual Sales in Million Doses for the Years 2020 through 2025
- EXHIBIT 26: Japanese Current & Future Analysis for COVID-19 Vaccines Market: Annual Sales in US$ Million for the Years 2020 through 2025
- CHINA
- Market Analysis
- WHO Recognizes Sinopharm's COVID-19 Jab as Effective & Safe
- Chinese Regulator Gives Nod to COVID-19 Vaccine from Sinovac Life Sciences
- China Approves Sinopharm's Vaccine
- BioNTech's Shot to Become First Western COVID-19 Vaccine to Secure Authorization in China
- Countries Relying on the Chinese COVID-19 Vaccines
- Trials Indicate Neutralizing Effect of Chinese COVID-19 Vaccines on South African & UK Variants
- Market Analytics
- EXHIBIT 27: Chinese Current & Future Analysis for COVID-19 Vaccines Market: Annual Sales in Million Doses for the Years 2020 through 2025
- EXHIBIT 28: Chinese Current & Future Analysis for COVID-19 Vaccines Market: Annual Sales in US$ Million for the Years 2020 through 2025
- EUROPE
- EU Urges Nations to Focus on COVID-19 Vaccine Sharing & Export to Beat the Pandemic (May, 2021)
- COVID-19 Vaccine Drive Gathers Pace in Europe after Initial Glitch
- EU Approves Pfizer's Vaccine
- EU Eyes on Milestone Deal to Get 1.8 Billion Doses of Pfizer-BioNTech COVID-19 Vaccine
- European Agency Makes Changes to Ramp Up Supply & Manufacturing Capacity of Pfizer & Moderna COVID-19 Vaccines
- BioNTech to Scale up Vaccine Production to Fill Supply Gaps and Support Vaccination Efforts in the EU
- Europe's Horizon 2020
- EU Demands Delivery of 120 Million COVID-19 Vaccine Doses from AstraZeneca
- EU's Assessment Prompts Spain to Restart Use of Oxford-AstraZeneca COVID-19 Vaccine
- Johnson & Johnson to Resume Shipment of Janssen COVID-19 Vaccine to Europe
- Apparent Side-Effects Prompt Denmark to Extend Suspension of Oxford-AstraZeneca COVID-19 Vaccine
- Market Analysis
- UNITED KINGDOM
- Vaccine Passport
- UK Wins COVID-19 Vaccine Race with Approval of Pfizer-BioNTech Vaccine
- Vaccine Distribution Challenges
- The UK Approves AstraZeneca's Vaccine
- Oxford-AstraZeneca's COVID-19 Vaccine in the form of Nasal Spray, to be Tested Soon (March, 2021)
- Moderna Modifies Supply Contract with UK to Deliver Additional Doses of COVID-19 Vaccine
- UK's Independent Vaccine Deals
- GSK to Aid Production of Novavax's COVID-19 Vaccine for Distribution within UK
- FRANCE
- France Embarks on Plans to Offer COVID-19 Vaccine Free to Citizens
- France Suggests mRNA Vaccines for Second Coronavirus Shot After AstraZeneca's First Shot
- GERMANY
- Germany Readies COVID-19 Vaccine Centers
- Germany Allows the Use of J&J Vaccine
- Germany Continues to Limits Use of AstraZeneca in under 60s Despite Recommendations from EMA Ruling
- SPAIN
- Spain Prioritizes Frontline Healthcare Providers for Immunization Policy
- Spain to Donate Vaccines to Latin America and Caribbean
- ITALY
- Italy Plans to Produce mRNA Vaccines Domestically
- RUSSIA
- Gamaleya Institute's Sputnik V Vaccine Trials Show Promise with 92% Efficacy
- CanSino Obtains Approval for Phase III Trial of COVID-19 Vaccine in Russia
- GREECE
- COVID-19 Vaccine Availability in Greece
- NORWAY
- Norway Bans AstraZeneca COVID-19 Vaccine
- Market Analytics
- EXHIBIT 29: European Current & Future Analysis for COVID-19 Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia, and Rest of European Markets - Independent Analysis of Annual Doses in Millions for Years 2020 through 2025
- EXHIBIT 30: European 5-Year Perspective for COVID-19 Vaccines by Geographic Region - Percentage Breakdown of Million Doses for France, Germany, Italy, UK, Spain, Russia, and Rest of European Markets for Years 2020 & 2025
- EXHIBIT 31: European Current & Future Analysis for COVID-19 Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia, and Rest of European Markets - Independent Analysis of Sales in US$ Million for Years 2020 through 2025
- EXHIBIT 32: European 5-Year Perspective for COVID-19 Vaccines by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, Russia, and Rest of European Markets for Years 2020 & 2025
- ASIA-PACIFIC
- Market Analysis
- SinoVac's Vaccine in Asian Countries
- INDIA
- Gasping with Deadly Second Wave of COVID-19, India Plans to Secure 2 Billion Shots
- Second Wave of Covid-19 in India Attributed to Variants
- Indian Government Initiates COVID-19 Vaccination Drive
- India Makes Notable Contribution in Production of Vaccines
- AstraZeneca's Covishield Receives Emergency Use Approval in India
- EXHIBIT 33: Introduction of COVID-19 Vaccine in Priority Group: India
- Spike in New Cases Coerces India to Briefly Suspend Export of Oxford-AstraZeneca COVID-19 Vaccine
- Bharat Biotech`s Covaxin Gets Approval
- Bharat Biotech Seeks Government Financial Backing to Ramp up Production of Covaxin
- Russia Moves Ahead at Breakneck Speed to Mass Produce Sputnik VVaccine in India
- Bharat Biotech & SII on Capacity Expansion Mode
- Trial Indicates Decent Efficacy of Covaxin against B.1.617 Variant of COVID-19
- IIL Partners with Bharat Biotech to Produce Active Drug Substance for Covaxin
- J&J Vaccine to Be Available in India by Fourth Quarter of 2021
- Novavax's Clinical Trials for Corovax COVID-19 Vaccine in India Holds High Relevance amid Second Wave
- Dr Reddy`s Rolls out Sputnik V Covid-19 Vaccine in India
- Delayed Launch of Corovax in India
- Pfizer Looks Forward to Make its COVID-19 Vaccine Available in India
- DCGI Approves Phase 2 and 3 Clinical Trials of COVAXIN on Children Aged 2 to 18 Years
- Moderna, Pfizer Vaccines Less Effective against COVID-19 Mutant Found in India
- AUSTRALIA
- Australia to Invest On Novel Coronavirus Vaccines for Wider Region
- Australia to Buy 20 Million Extra Doses of Pfizer COVID-19 Vaccine, Pivoting away from AstraZeneca
- NEW ZEALAND
- New Zealand Acquires Ultra-Cold Freezers to Store Pfizer's COVID-19 Vaccine
- SOUTH KOREA
- Fresh COVID-19 Cases Prompt South Korea to Heighten Curbs
- Johnson & Johnson Inches Closer to Approval for its COVID-19 Vaccine in South Korea
- INDONESIA
- Indonesia Negotiates Additional COVID-19 Vaccines from China and GAVI
- Indonesia Gets First Consignment of COVID-19 Vaccine from China's Sinovac
- BANGLADESH
- Serum Institute of India to Offer 3 Crore Doses of COVID-19 Vaccine to Bangladesh
- Market Analytics
- EXHIBIT 34: Asia-Pacific Current & Future Analysis for COVID-19 Vaccines by Geographic Region - Australia, India, New Zealand, and Rest of Asia-Pacific Markets - Independent Analysis of Annual Doses in Millions for Years 2020 through 2025
- EXHIBIT 35: Asia-Pacific 5-Year Perspective for COVID-19 Vaccines by Geographic Region - Percentage Breakdown of Million Doses for Australia, India, New Zealand, and Rest of Asia-Pacific Markets for Years 2020 & 2025
- EXHIBIT 36: Asia-Pacific Current & Future Analysis for COVID-19 Vaccines by Geographic Region - Australia, India, New Zealand, and Rest of Asia-Pacific Markets - Independent Analysis of Dollar Sales in US$ Million for Years 2020 through 2025
- EXHIBIT 37: Asia-Pacific 5-Year Perspective for COVID-19 Vaccines by Geographic Region - Percentage Breakdown of Dollar Sales for Australia, India, New Zealand, and Rest of Asia-Pacific Markets for Years 2020 & 2025
- THE MIDDLE EAST
- Market Analysis
- BAHRAIN
- Bahrain Becomes the Second Country to Offer Emergency Use Approval to Pfizer's Vaccine
- Sinopharm's Vaccine Doses Reach Bahrain
- SAUDI ARABIA
- COVID-19 Vaccine Production in the UAE
- IRAN
- Iran Procures Vaccine Doses
- AFGHANISTAN
- Afghanistan to Procure COVID-19 Vaccines
- TURKEY
- COVID-19 Vaccines in Turkey
- ISRAEL
- COVID-19 Vaccines for Israel
- SYRIA
- Syria Obtains AstraZeneca Vaccines, the first for the Country
- Market Analytics
- EXHIBIT 38: The Middle East Current & Future Analysis for COVID-19 Vaccines Market: Annual Sales in Million Doses for the Years 2020 through 2025
- EXHIBIT 39: The Middle East Current & Future Analysis for COVID-19 Vaccines Market: Annual Sales in US$ Million for the Years 2020 through 2025
- AFRICA
- Market Analysis
- SOUTH AFRICA
- New Virus Variant in South Africa Creates a Challenge
- South Africa Halts AstraZeneca's Vaccination
- Highly Infectious COVID-19 Variant Spurs Countries to Impose Travel Ban from South Africa
- South Africa: The First Country in Africa to Start Vaccine Clinical Trial
- WHO Urges African Nations to Prepare for COVID-19 Vaccine Rollout
- South Africa to Resume J&J Jab Vaccination
- Aspen to Manufacture Johnson & Johnson's COVID-19 Vaccine in South Africa
- China to Deliver Potential COVID-19 Vaccine to Africa for Free
- CEPI Identifies Biovac Institute as Potential Manufacturer in South Africa
- EGYPT
- Market Analytics
- EXHIBIT 40: African Current & Future Analysis for COVID-19 Vaccines Market: Annual Sales in Million Doses for the Years 2020 through 2025
- EXHIBIT 41: African Current & Future Analysis for COVID-19 Vaccines Market: Annual Sales in US$ Million for the Years 2020 through 2025
- LATIN AMERICA
- Market Analysis
- Mass COVID-19 Vaccination Campaigns Launched in Latin American Countries
- BRAZIL
- Brazil Signs Deal to Buy Additional 100 Million Doses from Pfizer/BioNTech
- Brazilian Town Serrana Beats COVID-19 with China`s Sinovac Vaccine
- Brazil, Turkey Announce Vaccination Plans for Chinese Vaccine
- Brazil to Receive 15 Million Doses of AstraZeneca's COVID-19 Vaccine
- GSK to Aid Production of Novavax's COVID-19 Vaccine for Distribution within UK
- Brazil Blocks Import of Russian Sputnik V COVID-19 Vaccine over Efficacy & Safety Concerns
- MEXICO
- Mexico's Cofepris Approves Emergency Use of Pfizer's COVID-19 Vaccine
- ARGENTINA
- Argentina Secures 22 Million Doses of AstraZeneca's COVID-19 Vaccine
- CHILE AND PERU
- Chile, Peru Approve Clinical Trials for AstraZeneca's COVID-19 Vaccine
- Chile Struggles with Escalating Cases of COVID-19 despite Massive Rollout of Vaccine
- CanSinoBIO Secures Emergency Use Authorization for COVID-19 Vaccine in Chile
- URUGUAY
- Uruguay Aims to Begin COVID-19 Vaccination Drive in April 2021
- Market Analytics
- EXHIBIT 42: Latin American Current & Future Analysis for COVID-19 Vaccines by Geographic Region - Brazil, Mexico, and Rest of Latin American Markets - Independent Analysis of Annual Doses in Millions for Years 2020 through 2025
- EXHIBIT 43: Latin American 5-Year Perspective for COVID-19 Vaccines by Geographic Region - Percentage Breakdown of Million Doses for Brazil, Mexico, and Rest of Latin American Markets for Years 2020 & 2025
- EXHIBIT 44: Latin American Current & Future Analysis for COVID-19 Vaccines by Geographic Region - Brazil, Mexico, and Rest of Latin American Markets - Independent Analysis of Dollar Sales in US$ Million for Years 2020 through 2025
- EXHIBIT 45: Latin American 5-Year Perspective for COVID-19 Vaccines by Geographic Region - Percentage Breakdown of Dollar Sales for Brazil, Mexico, and Rest of Latin American Markets for Years 2020 & 2025
- EXHIBIT 46: Funding Deals for COVID-19 Vaccine R&D: 2020 & 2021
- Licensing and Partnership Deals Worldwide Propel Vaccine Production
- EXHIBIT 47: COVID-19 Deals Worldwide - Jan 2020 to May 2021
- Reining in Pandemic Necessitates Fair Access to Resources Globally
- Vaccine Alliances Ensure Supplies for All
- Amazon On-Site Vaccination Initiative
- Vaccine Delivery and Success - The Big Task Ahead
- The Development and Delivery Challenge
- Planning Amid Uncertainty
- The Need for a New Approach
- Building Cold-chain Storage Infrastructure
- Hopes Pegged to Universal Vaccines with Enhanced Temperature Stability
- Asians Add Vantage
- Handling the Skeptical Consumer
- Efficient Task Force for Greater Success Rates
- The Importance of Site Selection
- Workforce Training
- Consumer Education
- Government's Role in Vaccine Distribution
- Building Cold Chains Crucial for Vaccine Supplies in Africa, Asia and South America
- Bracing up Networks to Combat Crisis
- The Most Extensive Vaccine Program in the History of Mankind Is Upon Us
- Fair Distribution of COVID-19 Vaccine
- Vaccine Nationalism to Hamper Equitable Distribution of Vaccines
- COVAX Created to Ensure Fair and Universal Access to COVID-19 Vaccine
- COVAX Inks Additional Deals for Global Rollout of COVID-19 Vaccines
- African Countries Become Part of the COVAX Facility for Timely Access to Successful Vaccines
- COVAX Advance Market Commitment (AMC)
- World Economic Forum to Push COVID-19 Vaccine Production Capability
- Pushing Manufacturing Capacity to Fulfil Global Demand
- Technology Transfer and Other Payments
- Inactivated Vaccines
- Inactivated Vaccine Candidate in Preclinical Development: As on May 14, 2021
- Protein-Subunit Vaccines
- Protein-Subunit Vaccine Candidate in Preclinical Development: As on May 14th, 2021
- Non-Replicating Viral-Vector
- Non-Replicating Viral Vector Vaccine in Preclinical Development: As on May 14th, 2021
- Replicating Viral Vector Vaccine Candidate in Preclinical Development: As on May 14th, 2021
- Nucleic Acid Vaccines
- RNA Vaccine Candidate in Preclinical Studies: As on May 14, 2021
- DNA Vaccine Candidate in Preclinical Studies: As on May 14, 2021
- Replicating Bacteria Vector
- Live Attenuated Vaccines (LAVs)
- Live Attenuated Virus Candidate in Preclinical Studies: As on May 14, 2021
- Live Attenuated Bacterial Vector Candidate in Preclinical Studies: As on May 14th, 2021
- Virus-like Particle Vaccines
- Virus-like Particles (VLP) Vaccine Candidate in Preclinical Development: As on May 14th, 2021
- Moderna, Inc. (USA)
- Pfizer Inc./BioNTech (US/Germany)
- AstraZeneca/University of Oxford (The UK)
- Johnson & Johnson (USA)
- CanSino Biologics, Inc. (China)
- China National Pharmaceutical Group Co., Ltd. (Sinopharm) (China)
- Sinovac Biotech Ltd. (China)
- Novavax, Inc. (US)
- Inovio Pharmaceuticals (US)
- Sanofi/GlaxoSmithKline (France/UK)
17. SELECT CORPORATE DEVELOPMENTS IN THE COVID-19 MARKET SPACE: 2021
III. COMPETITION
- Total Companies Profiled: 335
Note: Product cover images may vary from those shown
- Moderna, Inc.
- Pfizer Inc./BioNTech
- AstraZeneca/University of Oxford
- Johnson & Johnson
- CanSino Biologics, Inc.
- China National Pharmaceutical Group Co., Ltd. (Sinopharm)
- Sinovac Biotech Ltd.
- Novavax, Inc.
- Inovio Pharmaceuticals
- Sanofi/GlaxoSmithKline
- Gamaleya Institute
Note: Product cover images may vary from those shown
